Prevalence-based Health and Economic Model of the Bivalent Versus the Quadrivalent Human Papillomavirus (HPV) Vaccine

Trial Information

Additional Health and Economic Impact of the Bivalent Versus the Quadrivalent HPV Vaccine in Taiwan: Results of a Prevalence-based Model

This study uses a prevalence-based model (by using efficacy data from each vaccine's
respective trials and published cost data for Taiwan) which estimates the differences in
lesions, genital warts, cervical cancer and costs from a healthcare payer's perspective
prevented between HPV-1 and HPV-2 vaccines during one year (when all women are vaccinated).
It also analyses costs from a societal perspective.

Inclusion Criteria:

- Female subjects vaccinated with either HPV-1 or HPV-2 vaccines in Taiwan
(hypothetical group).

Exclusion Criteria:

- Not applicable.

Type of Study:

Observational

Study Design:

N/A

Outcome Measure:

Annual number of lesions prevented by each vaccine

Outcome Time Frame:

Over a one-year period

Safety Issue:

Principal Investigator

GSK Clinical Trials

Investigator Role:

Study Director

Investigator Affiliation:

GlaxoSmithKline

Authority:

Taiwan: Food and Drug Administration, Department of Health

Study ID:

114420

NCT ID:

NCT01702337

Start Date:

February 2010

Completion Date: